statistiche ricercatore

Continente	#
NA - Nord America	2.081
EU - Europa	1.252
AS - Asia	1.186
SA - Sud America	19
AF - Africa	16
OC - Oceania	16
Continente sconosciuto - Info sul continente non disponibili	10
Totale	4.580

Nazione	#
US - Stati Uniti d'America	2.015
CN - Cina	696
IT - Italia	382
DE - Germania	170
JP - Giappone	135
FR - Francia	117
GB - Regno Unito	113
IN - India	98
IE - Irlanda	75
SE - Svezia	56
ES - Italia	50
CA - Canada	49
KR - Corea	46
HK - Hong Kong	42
NL - Olanda	35
FI - Finlandia	33
PL - Polonia	32
TR - Turchia	29
BE - Belgio	27
VN - Vietnam	27
SG - Singapore	26
TW - Taiwan	26
UA - Ucraina	26
AT - Austria	20
GR - Grecia	18
MX - Messico	16
RO - Romania	16
PT - Portogallo	15
TH - Thailandia	14
AU - Australia	13
CZ - Repubblica Ceca	11
DK - Danimarca	9
NO - Norvegia	9
BR - Brasile	8
CH - Svizzera	8
MY - Malesia	8
RU - Federazione Russa	8
ID - Indonesia	7
EU - Europa	6
HU - Ungheria	6
IL - Israele	6
SN - Senegal	6
AM - Armenia	5
IR - Iran	5
NG - Nigeria	5
SI - Slovenia	5
AP - ???statistics.table.value.countryCode.AP???	4
CY - Cipro	4
SA - Arabia Saudita	4
AR - Argentina	3
BG - Bulgaria	3
CO - Colombia	3
EC - Ecuador	3
NZ - Nuova Zelanda	3
EG - Egitto	2
IS - Islanda	2
LB - Libano	2
PK - Pakistan	2
RS - Serbia	2
SK - Slovacchia (Repubblica Slovacca)	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
CU - Cuba	1
DZ - Algeria	1
EE - Estonia	1
LT - Lituania	1
PE - Perù	1
PH - Filippine	1
TN - Tunisia	1
TZ - Tanzania	1
UY - Uruguay	1
Totale	4.580

Nome	#
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer	1.235
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations	1.094
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer	439
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer	411
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer	272
Met-driven invasive growth involves transcriptional regulation of Arhgap12	211
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis	196
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer	169
Ron kinase transphosphorylation sustains MET oncogene addiction	168
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.	149
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer	102
An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.	91
The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.	70
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer	70
Totale	4.677

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	250	0	0	0	0	0	0	0	0	0	58	123	69
2019/2020	761	59	43	44	88	38	79	58	78	88	62	69	55
2020/2021	775	48	25	50	66	63	61	92	47	71	91	58	103
2021/2022	857	85	79	102	112	43	45	75	54	66	51	84	61
2022/2023	679	60	71	39	56	50	90	46	46	69	35	55	62
2023/2024	504	65	77	50	44	80	37	43	43	19	46	0	0
Totale													4.677

CINECA IRIS Institutional Research Information System